{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2003"],"data_sharing_plan":["IPD Sharing (as of October 2022): No"],"condition":["Colorectal Neoplasms"],"disease":["Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2026348"],"location":["Australia"],"study_start_month":["10"],"keyword":["Capecitabine","Antibodies","Antibodies, Monoclonal"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer","description":"The purpose of this clinical trial is to determine whether it is safe to treat patients with advanced colorectal cancer, with humanised A33 antibody tagged with radioactive iodine (131I-huA33) in combination with chemotherapy (capecitabine).","dates":{"creation":"2003-10-15"},"accession":"2026348","cross_references":{"ClinicalTrials___gov":["NCT00291486"]}}